# Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Study · id `cardio:ct-nct07614958` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07614958](<https://clinicaltrials.gov/study/NCT07614958>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07614958

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 426 participants.

## Technical summary

Registry record NCT07614958. Randomized; double masking; primary purpose treatment. Start 2026-05-06 (actual); primary completion 2027-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 426 participants (planned count; ClinicalTrials.gov record NCT07614958, source copy `cardio:ctgov-nct07614958-2026-06-09`, retrieved 2026-10-31)
- Started: 2026-05-06 (actual) (ClinicalTrials.gov record NCT07614958, source copy `cardio:ctgov-nct07614958-2026-06-09`, retrieved 2026-10-31)
- Primary completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07614958, source copy `cardio:ctgov-nct07614958-2026-06-09`, retrieved 2026-10-31)
- Completion: 2027-01 (anticipated) (ClinicalTrials.gov record NCT07614958, source copy `cardio:ctgov-nct07614958-2026-06-09`, retrieved 2026-10-31)
- Countries: United Kingdom (ClinicalTrials.gov record NCT07614958, source copy `cardio:ctgov-nct07614958-2026-06-09`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07614958-2026-06-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days
- Acronym: MEDICI
- Condition: Mixed Dyslipidemia
- Condition: Hypercholesterolaemia
- Intervention (Drug): Obicetrapib 10 mg/Bempedoic Acid Placebo
- Intervention (Drug): Bempedoic Acid 180mg/Placebo Obicetrapib
- Lead sponsor: A. Menarini International Licensing S.A.
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

## Provenance

Content hash: 81846704ad51776fbbe3e1a9913aa293b8a79d2121c3542838d6f9638494c8f6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
